List of Excipients in Branded Drug CLIMARA PRO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	CLIMARA PRO	estradiol and levonorgestrel	54868-5570	POVIDONE

Climara Pro Excipient Strategy and Commercial Opportunities

Last updated: August 27, 2026

Climara Pro is a once-weekly transdermal hormone-replacement patch combining estradiol and levonorgestrel. Its commercial value is tied to reliable seven-day delivery, skin adhesion, low irritation, dose uniformity, and protection of the fixed-dose combination. The strongest excipient opportunities are in adhesive chemistry, skin-permeation control, residual drug reduction, patch wear performance, and alternative manufacturing platforms rather than in conventional tablet-style formulation changes.

What is Climara Pro and how is it formulated?

Climara Pro is an estradiol/levonorgestrel transdermal system marketed by Bayer. The labeled system delivers approximately 0.045 mg of estradiol and 0.015 mg of levonorgestrel per day over a seven-day application period. The patch has a nominal active surface area of approximately 12.5 cm².[1]

Attribute	Climara Pro
Active ingredients	Estradiol and levonorgestrel
Delivery route	Transdermal
Application frequency	Once weekly
Estradiol delivery rate	Approximately 45 mcg/day
Levonorgestrel delivery rate	Approximately 15 mcg/day
Dosage form	Multilayer transdermal patch
Product type	Fixed-dose estrogen/progestin combination
Regulatory pathway	NDA 021241
Primary commercial use	Menopausal hormone therapy

The patch uses a drug-containing adhesive matrix between a backing layer and a removable release liner. The matrix architecture allows the active ingredients to be dispersed in or associated with the adhesive rather than held in a separate liquid reservoir.[1]

Which excipients are strategically important?

In a transdermal patch, excipients are functional components of the delivery system. They determine drug diffusion, crystallization behavior, adhesive performance, skin tolerability, release kinetics, and shelf life.

The core excipient categories are:

Excipient or component class	Primary function	Commercial sensitivity
Acrylic pressure-sensitive adhesive	Holds the patch on skin and carries the drug matrix	High
Tackifiers or adhesive modifiers	Improve initial tack and sustained adhesion	Medium to high
Permeation enhancers	Increase movement of estradiol or levonorgestrel through skin	High
Solubilizers	Maintain active ingredients in the matrix	High
Antioxidants or stabilizers	Reduce oxidative degradation	Medium
Backing film	Controls occlusion, flexibility, and protection	High
Release liner	Protects the adhesive before use	Medium
Printing inks and coatings	Product identification and handling	Low to medium

The exact composition, grade, supplier, and processing history of the commercial adhesive matrix are important because small changes can alter drug release or adhesive behavior.

What excipient strategy does a Climara Pro generic require?

A generic developer must reproduce the relevant product performance, not merely match the nominal estradiol and levonorgestrel strengths. The formulation must address both pharmaceutical equivalence and transdermal performance.

Adhesive selection

The adhesive is the main formulation platform. A suitable adhesive must:

• Maintain adhesion for seven days.
• Permit controlled release of two chemically different steroids.
• Resist cold flow and edge lifting.
• Avoid excessive residue after removal.
• Tolerate sweat, bathing, friction, and body movement.
• Minimize erythema, itching, and sensitization.
• Preserve drug uniformity during storage.

Acrylic adhesives are attractive because they can be engineered across a broad range of polarity, glass-transition temperature, and tack. Silicone adhesives can provide good skin tolerability and clean removal, but they may require different strategies for steroid solubilization and drug loading. Polyisobutylene systems offer established transdermal use but can have limitations in drug solubility, cohesive strength, and long-term wear.

The commercial tradeoff is direct: a higher-tack adhesive may improve adherence but increase irritation and removal residue. A softer adhesive may improve conformability but create cold flow or handling problems.

Solubility and crystallization control

Estradiol and levonorgestrel have different physicochemical properties. A formulation must keep both actives sufficiently solubilized throughout shelf life and use. Crystallization can reduce the effective delivery rate, create dose nonuniformity, and complicate bioequivalence testing.

Potential approaches include:

• Selecting an adhesive with sufficient steroid solubility.
• Using compatible cosolvents or plasticizers.
• Controlling residual solvent and drying conditions.
• Reducing drug loading gradients during coating.
• Adding crystallization inhibitors.
• Using a multilayer or microstructured matrix.
• Optimizing the active-to-adhesive ratio.

The formulation should be evaluated by polarized microscopy, differential scanning calorimetry, X-ray diffraction, content uniformity testing, and in vitro release testing. A formulation that performs well immediately after manufacture can fail after accelerated aging if the drug crystallizes or migrates within the matrix.

Permeation enhancement

Permeation enhancers can increase flux through the stratum corneum, but their use has limits. An enhancer that increases estradiol delivery may increase levonorgestrel delivery disproportionately. It can also produce skin irritation, alter adhesive strength, or create a higher initial burst.

A commercially viable enhancer strategy should show:

1. Stable delivery across the labeled seven-day period.
2. Limited burst release after application.
3. Acceptable skin irritation rates.
4. Consistent delivery across different skin sites.
5. No material increase in interpatient variability.
6. Compatibility with the backing film and adhesive.

Potential enhancer classes include fatty acid esters, alcohols, glycols, terpenes, and other lipid-disrupting materials. The most attractive candidates are not necessarily the strongest enhancers. Moderate enhancement with better tolerability can provide a stronger regulatory and commercial profile.

What formulation patents may protect Climara Pro?

Transdermal product protection can extend beyond the active ingredients. Relevant claim categories may include:

• Estradiol/levonorgestrel fixed-dose combinations.
• Specific drug loading and delivery rates.
• Drug-in-adhesive matrix systems.
• Adhesive compositions.
• Backing and release-liner combinations.
• Permeation-enhancing excipient systems.
• Manufacturing and coating processes.
• Reduced-residue or improved-adhesion formulations.
• Treatment methods using a defined patch schedule.
• Packaging systems that limit moisture or oxidation.

The practical value of a formulation patent depends on claim scope and whether a generic can design around the claim while meeting FDA requirements. A narrow claim directed to a particular adhesive grade or excipient concentration may be easier to avoid than a broad claim covering the fixed-dose transdermal combination.

No patent number, expiration date, or active Orange Book listing should be treated as confirmed without reviewing the current FDA Orange Book, USPTO records, and relevant patent-family prosecution histories. The product label alone does not establish current patent status.[2,3]

What is the Orange Book status of Climara Pro?

Climara Pro is associated with NDA 021241. The FDA Orange Book is the controlling public source for listed patents and regulatory exclusivity associated with an approved small-molecule product.[2]

A current commercial assessment should distinguish among:

Regulatory asset	Relevance to Climara Pro
Active ingredient patent	Protects estradiol or levonorgestrel chemistry, though these molecules are old
Formulation patent	May cover the patch matrix, adhesive, or release profile
Method-of-use patent	May cover menopausal hormone-therapy use or dosing
Pediatric exclusivity	Usually not central to this product unless specifically granted
Orphan exclusivity	Not expected for the broad Climara Pro indication
Regulatory exclusivity	Likely less important than formulation and use patents for an established product
Trademark and trade dress	Can affect branding but not generic market entry

Because estradiol and levonorgestrel are long-established molecules, the principal barrier is product-specific transdermal development rather than active-ingredient exclusivity.

When does Climara Pro lose exclusivity?

The practical loss of exclusivity depends on the latest enforceable patent claims, litigation settlements, and FDA approval status of competing ANDAs. For an older transdermal product, commercial exclusivity can erode before a complete cessation of branded sales because:

• A generic may launch at risk.
• A settlement may authorize entry before the latest patent expiration.
• A competing estradiol patch may substitute for some demand.
• Physicians may switch patients to separate estrogen and progestin regimens.
• Pharmacy benefit managers may impose substitution or formulary pressure.

The relevant timeline is:

Event	Commercial implication
FDA approval of an ANDA	Establishes regulatory readiness
Paragraph IV notice	Starts potential patent litigation
45-day litigation window	Can trigger a 30-month stay under applicable conditions
District-court settlement	May establish an agreed launch date
First generic approval	Creates substitution potential
First commercial launch	Begins direct price pressure
Multiple generic approvals	Accelerates reimbursement erosion

Are Paragraph IV challenges likely?

Paragraph IV risk is technically plausible because the product contains old active ingredients and uses a conventional transdermal dosage form. The principal challenge would likely focus on formulation, delivery equivalence, method of use, or patent validity rather than active-ingredient novelty.

A generic sponsor could pursue:

• A Paragraph IV certification against listed formulation patents.
• A Paragraph III certification if it accepts a later entry date.
• A section viii statement carving out a patented method of use.
• A formulation design-around that avoids specific adhesive or enhancer claims.

Transdermal products can present higher development risk than oral generics. The sponsor must establish drug release, adhesion, irritation, residual drug, and systemic exposure performance. That risk can delay launch even where patent barriers are limited.

What excipients create the strongest commercial opportunities?

Next-generation acrylic adhesives

Suppliers that offer low-irritation, high-tack acrylic systems can target hormone patches, nicotine patches, analgesic patches, and cardiovascular delivery systems. The most valuable platform would combine:

• Seven-day adhesion.
• Low skin stripping.
• Low residue.
• High steroid solubility.
• Stable coating viscosity.
• Consistent release after aging.

A supplier with regulatory experience and a qualified pharmaceutical grade has an advantage over a low-cost industrial adhesive provider.

Silicone adhesive platforms

Silicone systems may offer improved skin comfort and clean removal. Their limitations include higher material cost, different drug-solubilization requirements, and potential challenges in achieving the same flux for both hormones.

A silicone-based Climara Pro alternative could be commercially differentiated if it demonstrates lower irritation, better adherence during bathing, or improved removal characteristics. It would likely require extensive bridging work because changing the adhesive can materially affect delivery.

Low-residue formulations

Patients may discontinue or avoid patches because of residue, edge lifting, visible wear, or difficulty removing the system. A low-residue matrix could support premium positioning in branded lifecycle management or private-label products.

The opportunity is strongest if the formulation maintains adhesion without relying on aggressive tackifiers or high plasticizer content.

Enhanced packaging

Packaging can protect patch performance by controlling moisture, oxygen, and solvent loss. Individual foil pouches with improved barrier properties may extend shelf life or reduce variability in sensitive formulations.

Packaging improvements can support a supplemental application, line extension, or manufacturing transfer. They are less likely to create durable standalone exclusivity unless combined with a clinically meaningful product improvement.

Microneedle and hybrid systems

Microneedle-assisted delivery could improve steroid delivery or reduce dependence on conventional chemical permeation enhancers. The commercial barriers are substantial:

• Device-drug combination-product regulation.
• Manufacturing complexity.
• Patient acceptability.
• Need for dose consistency.
• Higher unit cost.
• Possible need for new clinical studies.

Microneedles are more suitable for a differentiated follow-on product than for a low-cost ANDA strategy.

What manufacturing and intellectual-property barriers affect market entry?

The main manufacturing barrier is uniform, reproducible coating of a low-dose two-drug matrix over a large web. Critical process variables include:

• Mixing order.
• Drug particle size and dispersion.
• Coating thickness.
• Drying temperature.
• Residual solvent.
• Web tension.
• Lamination pressure.
• Die cutting.
• Pouch sealing.
• Storage humidity.

A manufacturer must also control drug migration between the matrix, backing, liner, and pouch. Adhesive transfer during die cutting or pouch storage can produce failures that are not evident in early laboratory batches.

Potentially defensible manufacturing IP includes solvent-free coating, continuous mixing, controlled crystallization, multilayer coating, and methods that reduce drug loss during drying. Process patents are commercially useful when they materially lower scrap, improve content uniformity, or enable a narrower specification range.

What generic launch scenarios exist for Climara Pro?

Scenario 1: Single generic launch

The first approved generic may receive strong substitution support but face limited price erosion if only one supplier is available. The branded product can retain demand through physician familiarity, supply reliability, and patients who experience adhesion differences with the generic.

Scenario 2: Multiple generic launches

Several approved generics would increase payer leverage and accelerate price reductions. Patch products may still maintain higher margins than simple oral generics because manufacturing capacity and bioequivalence development are more specialized.

Scenario 3: Authorized generic or branded alternative

An authorized generic can allow the sponsor to capture lower-price demand while protecting manufacturing scale and channel relationships. A branded alternative could compete on adhesive performance, skin tolerability, package design, or patch visibility.

Scenario 4: Therapeutic substitution

Clinicians may switch patients to estradiol-only patches, oral hormone therapy, vaginal estrogen, or separate estrogen and progestin products. This creates competitive pressure independent of Climara Pro patent expiry.

How does Climara Pro compare with competing hormone-delivery products?

Product category	Competitive advantage	Excipient opportunity
Estradiol-only patch	Broader patch availability and simpler formulation	Adhesion, low-dose uniformity, skin tolerability
Oral estrogen/progestin	Lower manufacturing complexity	Solubility, modified release, fixed-dose combinations
Vaginal estrogen	Local therapy and lower systemic exposure	Mucoadhesive systems, local retention
Gel or spray	Flexible dosing and no patch residue	Solubilization, evaporation control, dose metering
Separate estrogen and progestin	Dose flexibility	Combination-patch convenience remains an advantage
Long-acting implant or injection	Reduced dosing frequency	Device and sustained-release barriers

Climara Pro’s main product-level advantage is convenience: one weekly patch supplies both hormones. Its main formulation vulnerability is the need to balance two active ingredients in one adhesive matrix while maintaining consistent skin delivery.

What is the revenue exposure from Climara Pro generic entry?

Bayer does not generally report Climara Pro revenue as a separately disclosed public line item. Revenue exposure must therefore be assessed through broader women’s-health reporting, prescription volume, payer mix, geographic sales, and the relative contribution of hormone-therapy products.

Commercial exposure depends on:

• Share of prescriptions filled through substitution-sensitive channels.
• Availability of generic or authorized-generic alternatives.
• Patient adherence to weekly patch therapy.
• Reimbursement differences between branded and generic patches.
• Product recalls or manufacturing interruptions.
• Physician willingness to switch stable patients.
• Competition from estradiol-only products and nonpatch therapies.

For excipient suppliers, the opportunity is less dependent on the absolute brand revenue than on the size of the broader transdermal hormone-therapy market and the number of sponsors seeking differentiated follow-on products.

What is the biosimilar risk for Climara Pro?

Climara Pro has no biosimilar risk because it is a chemically synthesized small-molecule combination product, not a biologic. The relevant competitors are ANDA-based generics, authorized generics, 505(b)(2) products, and therapeutically substitutable hormone-delivery products.

A 505(b)(2) strategy could be appropriate for a materially modified patch, including a different adhesive platform, new delivery profile, new application interval, or clinically differentiated tolerability profile. The tradeoff is a higher development burden than an ANDA and potentially greater freedom to claim product improvements.

Key Takeaways

• Climara Pro is a once-weekly estradiol/levonorgestrel transdermal patch using a drug-containing adhesive matrix.
• Adhesive chemistry is the central excipient and commercial-control point.
• The best formulation opportunities are low-irritation adhesion, reduced residue, stable dual-drug solubilization, and consistent seven-day delivery.
• Generic entry is more likely to be constrained by transdermal development complexity than by active-ingredient patents.
• Paragraph IV strategies may target formulation or method-of-use claims rather than estradiol or levonorgestrel chemistry.
• No biosimilar pathway applies; ANDA, authorized-generic, and 505(b)(2) pathways are the relevant competitive routes.
• Patent conclusions require current review of the FDA Orange Book and USPTO records because product labeling does not establish live patent rights.
• Excipient suppliers with pharmaceutical-grade acrylic, silicone, or low-residue adhesive platforms have the clearest near-term commercial opportunity.

FAQs About Climara Pro Excipient and Commercial Strategy

Can a generic Climara Pro use a different adhesive?

Yes. A generic may use a different adhesive if it meets applicable pharmaceutical-equivalence, quality, performance, and bioequivalence requirements and does not infringe enforceable patent claims.

Which excipient is most important in a Climara Pro follow-on product?

The pressure-sensitive adhesive is usually the most important excipient because it controls adhesion, drug dispersion, release, skin tolerability, and removal behavior.

Could a new Climara Pro patch qualify for 505(b)(2) approval?

Yes. A materially modified patch may be suitable for a 505(b)(2) application if the sponsor can rely partly on existing findings while providing data for the new formulation, delivery system, or clinical use.

Is a lower-residue Climara Pro patch commercially valuable?

Yes. Lower residue can improve patient acceptance, reduce discontinuation, and support differentiation against conventional matrix patches, provided adhesion and drug delivery remain equivalent.

Are estradiol and levonorgestrel patents the main market-entry barrier?

No. These are established active ingredients. The more relevant barriers are patch formulation patents, manufacturing know-how, transdermal performance, regulatory testing, and commercial scale-up.

References

1. U.S. Food and Drug Administration. (n.d.). Climara Pro (estradiol and levonorgestrel transdermal system) prescribing information. Bayer HealthCare Pharmaceuticals Inc.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2022). ANDAs for certain highly purified synthetic peptides and other complex drug products: Guidance for industry. https://www.fda.gov/

4. U.S. Food and Drug Administration. (2016). Transdermal and topical delivery systems: Product development and quality considerations: Draft guidance for industry. https://www.fda.gov/

5. U.S. Pharmacopeia. (n.d.). General chapter <724> drug release. United States Pharmacopeial Convention.